Guard Therapeutics (publ) (“Guard” or the “Company”) announces today that Redeye Aktiebolag (“Redeye”) has been appointed as financial advisor in connection with the strategic review announced by the Company in its press release dated 4 December 2025. The review includes an assessment of potential strategic alternatives, including the identification of possible counterparties for a merger or a reverse acquisition.
Guard Therapeutics (publ) has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will assume the role of Certified Adviser on 8 December 2025.
Guard Therapeutics (publ) (“Guard” or the “Company”) today announces that the Board of Directors has resolved to commence an exploratory process regarding strategic alternatives, including identifying potential candidates for a merger or reverse takeover (RTO) of the Company. Guard believes that its listing on Nasdaq First North Growth Market in Stockholm, together with its cash position, may represent significant value for potential counterparties.
Guard Therapeutics (public) (“Guard” or “the Company”) today provides an assessment of the full results from the Phase 2b POINTER study evaluating RMC-035 in patients undergoing open-heart surgery. As previously communicated, the study did not meet its primary or key secondary efficacy endpoints, although promising signals were observed with the 30 mg dose level, particularly in reducing acute kidney injury. Given the overall negative outcome of the study, the Company has decided to discontinue all further development of RMC-035.
Guard Therapeutics (publ) today announced top-line results from the company’s Phase 2b POINTER study evaluating the investigational drug candidate RMC-035 as a kidney-protective therapy in patients undergoing open-heart surgery. The study did not meet its primary and key secondary efficacy endpoints.
Guard Therapeutics (publ) today announced that top-line results from the company’s Phase 2b POINTER study with the investigational drug candidate RMC-035 have been selected for oral presentation on November 6 as a Late-Breaking Clinical Trial at the scientific conference American Society of Nephrology (ASN) Kidney Week 2025 in Houston, TX, USA.
Guard Therapeutics (publ) today announced favorable efficacy results from additional analyses of the Phase 2a AKITA study with the investigational drug candidate RMC-035. The previously reported primary results demonstrated a robust improvement in kidney function following open-heart surgery. The new analyses strengthen these findings and show that RMC-035 provides kidney-protective benefits both in patients with and without acute kidney injury, and additionally reduces key biomarkers of kidney damage, including albuminuria, further supporting its kidney-protective potential. Selected results will be presented at the leading U.S. scientific conference ASN Kidney Week 2025.
Guard Therapeutics (publ) today announced that the last patient in its ongoing Phase 2b clinical trial, POINTER, has successfully completed the final scheduled follow-up visit 90 days after surgery (last patient last visit). The study is evaluating the company’s drug candidate, RMC-035, as a kidney-protective treatment for patients undergoing open-heart surgery.
Guard Therapeutics (publ) today announced that additional results from the Phase 2 AKITA study with the company’s drug candidate RMC-035 will be presented at the scientific conference Kidney Week 2025 organized by the American Society of Nephrology (ASN), in Houston, TX, USA. The new results are based on post hoc analyses of the previously completed and reported study and provide deeper insights into the potential of RMC-035 to preserve kidney function after open-heart surgery.
Guard Therapeutics (publ) today announced that the company will present at the following investor conferences ahead of the upcoming readout of the Phase 2b POINTER study: